We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Long-Term Liver Transplant Survival

By HospiMedica staff writers
Posted on 07 Jun 2005
A new study on the effect of donor age on survival and recurrence of hepatitis C after liver transplantation found that although it influenced short-term survival, it had no long-term effect.

Patients who undergo liver transplantation for cirrhosis due to hepatitis C are invariably re-infected with the virus after transplantation. More...
When the disease recurs, it often takes a more rapid and aggressive course. Survival rates of these patients appear to be worsening over the past few years.

In a study of 195 transplantations due to end-stage cirrhosis related to hepatitis C, researchers examined the impact of donor age, immunosuppression, and other factors on short- and long-term survival. Donor age was not associated with the development of severe fibrosis, and patients receiving treatment with maintenance steroids and/or azathioprine tended not to develop severe fibrosis. Hepatitis C, even if later discontinued, was an independent factor associated with worse fibrosis. Although several studies have suggested that less immunosuppression may be a viable strategy in minimizing progression of hepatitis C post-transplant, the authors found the situation to be more complex. They state that "the rapid withdrawal of steroids prevalent in recent years may have allowed an early reconstitution of the immune system and its exposure to a large number of HCV (hepatitis C virus)-infected liver cells, leading to immune mediated severe liver damage and thus to more frequent and severe forms of HCV recurrence.”

Another study on 10-year liver transplant survival found that alcohol relapse adversely affected survival rates only after 10 years. Both studies appeared in the April 2005 issue of Liver Transplantation, published by John Wiley, and are available on the company's website (www.interscience.wiley.com/journal/livertransplantation).





Related Links:
Liver Transplantation

Gold Member
12-Channel ECG
CM1200B
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Ureteral Dilatation Balloon
Dornier Equinox
Mammo DR Retrofit Solution
DR Retrofit Mammography
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.